Navigation Links
Selexis SA Launches SURE CHO-Mplus™ Libraries
Date:4/17/2013

Geneva, Switzerland (PRWEB) April 17, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification, cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the launch of its novel platform, SURE CHO-Mplus™ Libraries, which were designed and constructed to address a broad range of issues surrounding recombinant protein secretion including metabolic limitations, trafficking backlogs, improper folding and altered post-translational modifications.

With certain recombinant proteins, optimal expression cannot be achieved by elevated transcription alone. Low productivity can be the result of a myriad of issues including faulty cleavage and protein precipitation, improper folding, metabolic overload, or backlog in protein translocation or vesicle trafficking. Within each of the Company’s SURE CHO-Mplus™ Libraries, between 8-12 secretory components have been modified to address specific secretion bottlenecks, such as aberrant glycosylation or improper protein folding. The SURE CHO-Mplus™ Libraries have been shown to significantly improve production levels of a broad range of proteins including difficult-to-express monoclonal antibodies, enzymes, structural proteins and fusion proteins such as Fc-fusions and minibodies.

“The Selexis SURE CHO-Mplus™ Libraries are a novel and powerful advancement in biologic protein expression. Selexis’ libraries enable a multiplex approach to determine optimal secretory configurations for recombinant proteins,” said Dr. Igor Fisch, CEO, Selexis SA. “With the Selexis SURE CHO-Mplus™ Libraries, biopharmaceutical companies now have solutions for optimizing the commercial viability of biologic development programs including target expression campaigns that would be otherwise terminated because of protein secretion issues.”

The CHO-Mplus™ Libraries that address secretion bottlenecks include:

  •     CHO-Mplus™ ERsec
  •     CHO-Mplus™ ERfold
  •     CHO-Mplus™ VESIC
  •     CHO-Mplus™ GLYCO
  •     CHO-Mplus™ SURVIV
  •     CHO-Mplus™ DNArepair
  •     CHO-Mplus™ PROLIF

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:

Read the full story at http://www.prweb.com/releases/secretion_bottlenecks/recombinant_proteins/prweb10639998.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA to Partner and Exhibit at BIO 2013
2. Selexis SA to Present and Partner at the BIO-Europe Spring
3. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
4. Belafonte Launches Glamorous Cosmetics Line; Malena Belafonte Has Designed a Mineral Cosmetics Line for Women and Moms on the Go
5. Web Entrepreneur Launches JuicersAndCoffeeMakers.com, a Website Featuring Quality Kitchen Appliances
6. The Gluten Free Society Launches Gluten Sensitivity and Celiac Disease At-Home Testing
7. Astro-Clairvoyant Norah Guide with Premium Astrology Launches New Blog Series on Jupiter Transits
8. Cody Bramlett, Certified Russian Kettlebell Instructor (RKC), Launches Kettlebell X Boot Camp
9. PCOS Diva Launches Spring Meal Plans For Women With Polycystic Ovarian Syndrome
10. Minnesota Company, Altman Fitness, Launches Guaranteed Weight Loss Campaign
11. WTEC Launches New Website for Full Lineup of Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... IDC-Eating Disorder Care ... for the treatment program located in Royal Oak, Michigan. IDC, formerly known ... are focused on providing the highest standards in the field of eating disorder treatment ...
(Date:7/26/2017)... ... July 26, 2017 , ... BioPlus Specialty ... an updated version of the HCV Treatment Path app (version 4.4.0) to keep ... virus (HCV) infection. All of the latest HCV medications are included in this ...
(Date:7/25/2017)... Beach, Florida (PRWEB) , ... July 25, 2017 ... ... employee, Jennifer Haller, to the sales department joining as Regional Account Manager for ... relationships with contracted customers in the liquidation of their obsolete medical assets. , ...
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Donna Bergman, ... recently co-authored and published an article in the medical science journal Physical Medicine ... Both the article and the research that helped produce it, were written and ...
(Date:7/25/2017)... ... 25, 2017 , ... USHEALTH Group, Inc. has been announced ... World Awards®. The coveted annual CEO World Awards program encompasses the world’s best ... social responsibility, and milestones from every major industry in the world. Organizations from ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... and CAMBRIDGE, Massachusetts , July 25, 2017 ... repurposing drugs to treat rare nervous system diseases, has concluded ... develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). ... very promising results in a Phase 2 study conducted in ... office in the United States ...
(Date:7/24/2017)... , July 24, 2017 IBM (NYSE: IBM ... Magic Quadrant for Solid-State Arrays (SSA) for the fourth year ... According to Gartner, "Vendors in the Leaders quadrant have ... of Vision. A vendor in the Leaders quadrant has the ... drive the acceptance of new technologies. These vendors demonstrate a ...
(Date:7/21/2017)... N.Y. and EDMONTON, Alberta ... IBM ) scientists and the University of Alberta ... published new data in Nature,s partner journal, Schizophrenia ... algorithms helped predict instances of schizophrenia with 74% ... predicted the severity of specific symptoms in schizophrenia ...
Breaking Medicine Technology: